In fibro-inflammatory diseases where anti-IL6R therapy effectively targets immune cells but IL11 is also highly up-regulated (e.g. SSc or RA) it is possible that combination therapy with anti-IL11 may improve efficacy, which is an intriguing possibility. The gene discussed is IL11; the disease is systemic sclerosis.